Author

J Melville

Observed name: Jonathan Melville

Observed institutions: East Surrey Hospital, University of Saskatchewan, Surrey and Sussex Healthcare NHS Trust

OpenAlex ID: A5113101376

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39

Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12

ICU mortality rates in patients with sepsis before and after the Surviving Sepsis Campaign

2015 · J Melville, S Ranjan, et al. · Critical Care · 8

ICU mortality rates in patients with sepsis compared with patients without sepsis

2015 · J Melville, S Ranjan, et al. · Critical Care · 7

Sepsis screening protocol implementation: a clinician-validated rapid realist review

2024 · Jonathan Melville, Tracey Carr, et al. · BMJ Open Quality · 1

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases

Use of intravenous immunoglobulin to treat sepsis in a general ICU

2015 · Y Drakeford, J Kelly, et al. · Critical Care

Works count: 8

Citation count: 108

H-index: 5

I10-index: 3